Concile
concil GmbH is a German, family-owned distributor and developer of point-of-care rapid diagnostic tests and proprietary readers serving urology, gynecology, internal medicine practices, and pharmacies across Germany, with a portfolio spanning tumor, hormone, cardiac, infection, gastrointestinal, diabetes, and molecular diagnostics.
- Company typePrivate
- Founded2010
- HeadquartersFreiburg Im Breisgau, Germany
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Concile does
concil GmbH is a privately held, family-owned German medical diagnostics company headquartered in Freiburg im Breisgau that develops, produces, and distributes point-of-care (POC) rapid diagnostic tests and compatible measurement devices for physician practices in Germany. Founded around 2010, the company operates a mid-sized German Mittelstand with fourteen regional field sales teams covering all major territories and a Shopify-based e-commerce storefront for direct practice purchases. Its portfolio spans nine diagnostic categories — tumor diagnostics (CancerCheck®, ScheBo M2-PK, PSA/fPSA, HPV High Risk), hormone diagnostics (CrinoCheck® Vitamin D, TSH, Testosteron, LH-FSH, SHBG, AMH, Prolaktin), infection diagnostics (InfectCheck® CRP, SARS-CoV-2/RSV/FluA/FluB, Strep A, PCT, NeoPT), molecular STI testing (Pluslife NG/UU, TV/MG), cardiac diagnostics (MyoCheck® sPLA2-IIA, BodyCheck® HCY), gastrointestinal diagnostics (GastroPanel® Quick Test, ScheBo), diabetes diagnostics (BodyCheck® HbA1c), and sepsis diagnostics (SeptiLoop®), plus a sperm analysis system (SQA-iO) launched in 2025.
The underlying technology relies on lateral flow immunochromatographic assays and fluorescence immunoassays measured by proprietary readers (concile α1, Ω100, DUO, and GP Reader) that are RiliBÄK-compliant for German billing. Recent extensions into molecular diagnostics (Pluslife Mini Dock, launched November 2025) and digital urology (Streamcheck partnership, February 2026) signal a shift beyond purely consumable lateral flow products toward integrated hardware-software-and-molecular platforms. SeptiLoop, the company's flagship sepsis test, is CE-IVDR Class C certified and UKCA approved, representing the highest-risk in-vitro diagnostic classification in the portfolio.
The business model combines one-time hardware sales (readers at €5,870–€10,060+, SQA-iO bundles), recurring consumable test sales (typically packs of 20–25 tests), and — increasingly — subscription-style digital services bundled with hardware. Tests are billable to German private practice economics via the GOÄ fee schedule or as IGeL (individual health services), allowing practices to generate direct revenue from in-office testing; concile actively markets this practice-revenue angle through an online Wirtschaftlichkeitsrechner (profitability calculator). The company is ISO 13485:2016 certified and VDGH Code-compliant, with its own brand portfolio (CancerCheck, CrinoCheck, InfectCheck, GastroPanel, MyoCheck, BodyCheck, Pluslife, SeptiLoop) sitting alongside distributed partner products such as ScheBo assays. Management is led by Managing Director (Geschäftsführer) Michael Maier, and the company has no disclosed external funding rounds, acquisitions, or institutional investors.
Concile firmographics
Firmographics- Name
- Concile
- Legal name
- concil GmbH
- Website
- https://concile.de
- Company type
- Private
- Founded year
- 2010
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- concil GmbH is a German, family-owned distributor and developer of point-of-care rapid diagnostic tests and proprietary readers serving urology, gynecology, internal medicine practices, and pharmacies across Germany, with a portfolio spanning tumor, hormone, cardiac, infection, gastrointestinal, diabetes, and molecular diagnostics.
- Ownership category
- akta.pro rank
Concile industry classification
Industry- Product category
- Point-of-Care In-Vitro Diagnostics
- NAICS
- Medical Equipment and Supplies Manufacturing (3391)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Laboratory Analytical Instruments (3826), Wholesale-Medical, Dental & Hospital Equipment & Supplies (5047)
- akta.pro primary industry
- Infectious Disease POCT (Respiratory, STI, HIV, Sepsis) (HLAHAOAA)
- akta.pro secondary industries
- Pregnancy, Fertility & Women’s Health Rapid Tests (hCG, ovulation, vaginal infection) (HLAHAOAF), Remote Diagnostics & Home Testing Devices (Connected POC/At-Home Diagnostic Readers) (HLAHACAL)
Keywords
Where Concile is headquartered
LocationHeadquarters
- HQ city
- Freiburg Im Breisgau
- HQ country
- Germany
- HQ region
- Europe
Offices1 record
Markets served
Concile business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain, Infrastructure
Revenue model
- Rapid Diagnostic Tests: Sale of qualitative and quantitative rapid tests across multiple diagnostic categories including tumor, hormone, cardiac, infection, gastrointestinal, diabetes, and molecular diagnostics. Tests are sold in packages (typically 20 or 25 tests per unit) through e-commerce and field sales. Revenue is one-time per transaction with recurring purchase patterns driven by practice volume.
- Diagnostic Readers/Meters: Sale of proprietary Point-of-Care measurement devices including concile® α1 Reader, concile® Ω100 Reader, concile® DUO Reader, Pluslife Mini Dock, and GP Reader. These readers are required to perform quantitative rapid tests, creating a hardware + consumables model.
- GOÄ/IGeL Reimbursement: Tests are billable through GOÄ (Gebührenordnung für Ärzte) or as IGeL (Individuelle Gesundheitsleistungen). The company's profitability calculator demonstrates how practices can generate revenue through point-of-care testing, with each test having associated profit margins based on marker type and test volume.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| One time/ perpetual license | Pay-as-you-go | SeptiLoop® - 20 qualitative Lateral-Flow-Tests for sepsis diagnostics |
| One time/ perpetual license | Pay-as-you-go | SQA-iO Single - Sperm analysis system |
| One time/ perpetual license | Pay-as-you-go | SQA-iO Bundle - Complete sperm analysis system |
| Subscription | Annual | Streamcheck Portal - First year benefit |
| Unit Pricing | Pay-as-you-go | Standard Shipping |
Go-to-market motion3 records
Distribution channels2 records
Marketing channels5 records
Concile product offering
Product offeringCore offering
concile GmbH develops, manufactures, and distributes point-of-care rapid diagnostic tests and proprietary measurement readers for German medical practices. The portfolio spans nine diagnostic categories — tumor, hormone, cardiac, infection, gastrointestinal, diabetes, molecular (STI), sperm analysis, and sepsis diagnostics — using lateral flow immunochromatographic assays and nucleic acid testing. Tests are sold packaged in quantities of 20-25 alongside proprietary readers (concile α1, Ω100, DUO, GP Reader, Pluslife Mini Dock) that produce results in 10 to 35 minutes.
Product overview
Concile is a German medical diagnostics company offering a comprehensive portfolio of point-of-care rapid tests and compatible measurement devices for physician practices, pharmacies, and hospitals. The product ecosystem consists of: (1) quantitative and qualitative rapid tests across diagnostic categories including tumor diagnostics (CancerCheck UBC Rapid, ScheBo M2-PK Quick, CancerCheck PSA/fPSA, CancerCheck HPV High Risk), hormone diagnostics (CrinoCheck Vitamin D, TSH, Testosteron, Prolaktin, LH-FSH, AMH, SHBG), infection diagnostics (InfectCheck CRP, SARS-CoV-2/RSV/FluA/FluB, Strep A, PCT, NeoPT, Pluslife NG/UU, TV/MG), cardiac diagnostics (MyoCheck sPLA2-IIA, BodyCheck HCY), gastrointestinal diagnostics (GastroPanel Quick Test, ScheBo tests), diabetes diagnostics (BodyCheck HbA1c), and sepsis diagnostics (SeptiLoop); (2) point-of-care readers (concile α1 Reader, Ω100 Reader, DUO Reader, GP Reader) that measure quantitative rapid tests; and (3) molecular diagnostic systems (Pluslife Mini Dock) for nucleic acid testing of sexually transmitted infections. All products are CE-certified and manufactured under ISO 13485 quality management. Tests can be billed through GOÄ (private) or IGeL (individual health service) systems.
Differentiator
Problem solved
Functional benefit
Brands
- CancerCheck®: Rapid tests for bladder, colorectal, and prostate cancer detection as well as HPV-associated tumor diagnostics
- CrinoCheck®
- InfectCheck®
- concile® Readers (α1, Ω100, DUO)
- MyoCheck® / BodyCheck®
- Pluslife Mini Dock
- GastroPanel®
- SeptiLoop®
Products and services
- CancerCheck UBC Rapid Quantitative immunochromatographic rapid test for bladder cancer diagnostics measuring urinary cytokeratin 8/18 fragments (UBC) in 5-300 µg/l range with results in 10 minutes. For urology practices.
- CancerCheck UBC Rapid VISUAL Qualitative lateral flow rapid test for bladder cancer screening and monitoring via visual detection of urinary cytokeratin 8/18 fragments; no reader required.
Quantifiable outcome
- SeptiLoop® detects sepsis within 1 hour of infection onset with results in 3 hours, with up to 3x higher accuracy than standard tests
- +3 more outcomes
Companies that use Concile
Customer profileNamed customers1 record
Segments4 records
Ideal customer profiles3 records
Concile technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Concile partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core and minor.
- Streamcheck GmbHcoreStrategic partnership adding Streamcheck's digital urological diagnostics platform to concile's portfolio. Streamcheck enables uroflow and biomarker measurements both in practice and as structured home-based test series. The system includes a precise handheld device combined with a digital practice platform that automatically captures, evaluates, and presents measurement data for physician assessment. Medical device Class I (MDR). Concile partners receive Streamcheck Portal (€600 value) free for first year.
- DoctolibminorEuropean health-tech company with platform for doctor appointments, patient communication, and video consultations. Partnership likely enables appointment booking integration for concile's customers.
- HonorarExpert GmbHminorGerman provider of billing and compensation consulting for doctors. Supports practices with analysis, optimization, and ensuring correct billing according to GOÄ and EBM standards. Helps practices maximize revenue from point-of-care diagnostics.
Scale indicators3 records
Recent moves5 records
Expansion highlights6 records
Concile competitors and assessment
Company assessmentDirect peers
- EKF Diagnostics Holdings plc: UK-listed point-of-care diagnostics company with rapid test and reader products (QuikRead, Hemo Control) serving physician offices and decentralized care settings in Europe — a comparable mid-sized European POCT specialist.
- Boditech Med Inc. Korean POCT manufacturer with the AFIAS and ichroma reader platforms offering quantitative rapid tests across infection, cardiac, tumor, and hormone markers, distributed globally including Europe — directly comparable in product architecture (reader + consumables) and clinical menu.
- nal von minden GmbH: German POCT rapid test manufacturer offering a broad lateral flow and reader portfolio (CRP, HbA1c, hormones, infectious disease) sold through a similar direct-to-practice distribution model across German-speaking markets. Most direct structural peer to concile in size, geography, and channel.
- MöLab GmbH: German specialist distributor and developer of point-of-care rapid diagnostics for medical practices, offering a comparable range of infectious disease, cardiac, and hormone rapid tests with practice-facing field sales in the German market.
Broad incumbents
- bioMérieux SA: Global French-listed microbiology and IVD company with strong sepsis diagnostics franchise (BACT/ALERT, VIDAS) overlapping with concile's SeptiLoop® sepsis POC focus, and a broader infectious disease menu relevant to practice-level customers.
- Sekisui Diagnostics: Global clinical diagnostics and POCT company offering rapid tests and readers (ACON, OSOM brands) across infectious disease, cardiac, and women's health — overlapping menu categories with concile but with broader portfolio and global reach.
- Randox Laboratories Ltd. Northern Ireland-based global diagnostics manufacturer with extensive POCT and laboratory diagnostics portfolio. Listed as a concile technology/integration partner, indicating product overlap in IVD reagents and analyzers relevant to comparable practice settings.
- QuidelOrtho Corporation: Merged US diagnostics major combining Quidel's rapid immunoassay portfolio (Sofia, Triage) with Ortho's clinical chemistry and immunoassay systems, serving physician offices and hospitals globally — a broader incumbent operating in overlapping POC categories.
- Abbott Point of Care: Global POC diagnostics leader with the i-STAT system serving physician offices, urgent care, and hospital point-of-care across cardiac, infection, and metabolic markers — a major incumbent competing for the same practice-level rapid testing budgets.
Regional players
- Sentinel Diagnostics: Italian in-vitro diagnostics manufacturer producing rapid tests and clinical chemistry reagents for European hospital and practice laboratories — comparable mid-sized European specialty IVD company with overlapping clinical menu but primarily Southern European distribution.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
Concile social profiles
Digital presenceConcile compliance and trust
Trust signalCompliance3 records
Concile financial estimates
Financial estimateRevenue estimate
Valuation estimate
Concile leadership team
Management profileNumber of profiles
Profiles1 record
Concile funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Concile M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Concile
What does Concile do?
concile GmbH develops, manufactures, and distributes point-of-care rapid diagnostic tests and proprietary measurement readers for German medical practices. The portfolio spans nine diagnostic categories — tumor, hormone, cardiac, infection, gastrointestinal, diabetes, molecular (STI), sperm analysis, and sepsis diagnostics — using lateral flow immunochromatographic assays and nucleic acid testing. Tests are sold packaged in quantities of 20-25 alongside proprietary readers (concile α1, Ω100, DUO, GP Reader, Pluslife Mini Dock) that produce results in 10 to 35 minutes.
Is Concile a public or private company?
Concile is a private company. It is classified as family owned and is currently operating.
When was Concile founded?
Concile was founded in 2010. It employs 11 to 50 people.
Where is Concile based?
Concile is headquartered in Freiburg Im Breisgau, Germany, in the Europe region.
How does Concile make money?
Three revenue lines are on record. Rapid Diagnostic Tests are the primary driver. The others are diagnostic Readers/Meters and GOÄ/IGeL Reimbursement.
Who are Concile's main competitors?
Direct peers on record are EKF Diagnostics Holdings plc, Boditech Med Inc., nal von minden GmbH and MöLab GmbH. Broad incumbents are bioMérieux SA, Sekisui Diagnostics, Randox Laboratories Ltd., QuidelOrtho Corporation and Abbott Point of Care. Sentinel Diagnostics is listed as a regional player.
Does Concile have an API?
No public API is recorded for Concile.
What industry is Concile in?
Concile's product category is Point-of-Care In-Vitro Diagnostics. Its primary akta.pro industry code is HLAHAOAA, Infectious Disease POCT (Respiratory, STI, HIV, Sepsis), with a secondary code of HLAHAOAF, Pregnancy, Fertility & Women’s Health Rapid Tests (hCG, ovulation, vaginal infection). Its NAICS code is 3391 and its SIC code is 2835.